DCVMN Board

Mr. Venkatraman Sivaramakrishnan has been working at Bharat Biotech for over 10 years.. In his current role as Vice President International Business, he oversees Global Business operations, as well as. supports the management with go to market strategies, strategic alliances with international partners and development of advocacy teams. He has 30 plus years of experience in Vaccine and Biopharmaceutical Industry... Through his affiliation with organizations such as APCRI and as an industry invitee to RIA, he has been contributing to the prevention and control of Rabies in Asia. He holds an undergraduate degree in physical sciences and; Masters in General Management and Foreign Trade

Rachel Park has been with EuBiologics from prequalification to commercialization of Euvichol-Plus, oral cholera vaccine since 2015. She’s a director in international business at EuBiologics, responsible for marketing and collaboration with international stakeholders for its pipeline development. She was a venture capitalist funding biotechnology companies prior to joining in EuBioloigcs.

CEO of Bio-Manguinhos since 2017, holds a D.Phil. in Technology and Innovation Management from the University of Sussex (England) and a Master's in Science and Technology in Health from the National School of Public Health (Ensp/Fiocruz). He holds an Executive MBA from the Federal University of Rio de Janeiro (UFRJ/Coppead) and a specialization in Public Administration from the Brazilian School of Public Administration of the Getúlio Vargas Foundation (FGV). He holds a degree in Business Administration from Faculdades Integradas Bennett.

Zuma was executive director of the Foundation for Scientific and Technological Development in Health (Fiotec) from 2011 to 2017. At Bio-Manguinhos since 1994, he worked in restructuring processes and implemented management practices, such as the unit's Planning System. He managed the construction project of the Industrial Complex of Biotechnology in Health (CIBS), at the campus located in the Industrial District of Santa Cruz

Dr Sunil Gairola is the elected executive director at Serum Institute of India, (Missing bio), Responsible for vaccine quality with more than 30 years of experience in quality control, quality assurance and bioanalytic of vaccines and biosimilars. Collaborator to international initiatives of WHO, NVI, NIBSC, EDQM with interests in the harmonization of regulatory requirements of vaccines. Expert on Indian and USP Pharmacopoeia (IP) panels on vaccine and biosimilar monographs.

Andrew holds the position of General Manager at Shanghai Wotai Biotechnology, a Walvax subsidiary, and is the Director of Business Development at Walvax Biotechnology Ltd. He sustains more than 30 years of intercultural experience on molecular cancer drug, antibody therapeutics, human vaccine research, business development, global registration and sales & marketing. Through Andrew’s leadership and participation, Walvax and its subsidiary companies have received several grant and/or technical supports from DCVMN, Bill & Melinda Gates Foundation, PATH, CEPI and CHAI since 2014, in addition to the global business expansion of product registration and sales in numerous countries.

Sai Prasad is the Executive Director at Bharat Biotech. He is responsible for crucial decisions in the company with respect to operations, business development and International Collaborations. He has expertise in areas not restricted to product development, contract negotiations, technology licensing, mergers & acquisitions, fund raising, overall operations, etc.

Mr. Lobos is Engineer and MBA with 20-years’ professional experience in management, focused on new business development, engineering, start-up and operations of pharmaceutical companies. He has been working in vaccine companies for over 12 years. He holds a engineering degree from University of Buenos Aires.